Krasdale Foods Welcomes Liz Peralta-Foxwell as Director of Sales, Independent Channel

WHITE PLAINS, N.Y., Nov. 10, 2025 (GLOBE NEWSWIRE) — Krasdale Foods, the premier grocery distributor in the New York Metro area, has announced that Liz Peralta-Foxwell has joined the company as director of sales for the independent channel. In this role, Peralta-Foxwell will lead the field sales team and bring extensive experience in independent retail, […]

Blaqclouds, Inc. Announces Completion of Apollo ID Integration and Opens VIP Testing to First 500 Apollo Wallet Users

Blaqclouds, Inc. Announces Completion of Apollo ID Integration and Opens VIP Testing to First 500 Apollo Wallet Users GlobeNewswire November 10, 2025 ROBESONIA, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) — Blaqclouds, Inc. (OTC: BCDS), a leading Web3 infrastructure and blockchain technology company, is pleased to announce the successful completion of Apollo ID, a next-generation decentralized

Siebert Financial Corp. Announces Strategic Partnership with the Academy Veteran Bond ETF (VETZ) to Expand Veteran-Focused Financial Solutions and Education

(NASDAQ:SIEB),(NYSE:VETZ), NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — Siebert Financial Corp. (NASDAQ: SIEB) today announced a strategic partnership with the Academy Veteran Bond ETF (VETZ) managed by Academy Asset Management, the first post-9/11 veteran-owned and operated asset manager, to expand veteran-focused investment solutions, financial literacy initiatives, and media content supporting U.S. service members, veterans,

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 10, 2025 Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025 Expect to present interim analysis from approximately 25 six-month evaluable BCG-Unresponsive NMIBC patients in the ongoing

Global Ship Lease Reports Results for the Third Quarter of 2025

(NYSE:GSL), Forward contract cover locked in for 100% of 2025, 96% of 2026, and 74% of 2027. Maximizing strategic optionality while also returning capital to shareholders. Annualized dividend to increase to $2.50 per Class A Common Share. ATHENS, Greece, Nov. 10, 2025 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE: GSL) (the “Company”, “Global Ship

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities GlobeNewswire November 10, 2025 KUALA LUMPUR, Malaysia, Nov. 10, 2025 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“BioNexus” or the “Company”), a biotechnology company advancing precision diagnostics and gene-based technologies across Asia and

Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards Market

Vaxxas Appoints Veteran Vaccine Leader to Board as Company Advances Needle-Free Vaccine Patch Towards Market GlobeNewswire November 10, 2025 Seasoned global pharmaceutical executive, Mr Brent MacGregor, joins Vaxxas Board to accelerate self-administered HD-MAP vaccines for global use; SPRIM Global Investment's Co-Founder and Managing Partner, Mr Michael Shleifer appointed Board Observer following recent ~$90 million financing.

CoreCivic Announces $200 Million Increase to Share Repurchase Authorization

CoreCivic Announces $200 Million Increase to Share Repurchase Authorization GlobeNewswire November 10, 2025 BRENTWOOD, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that its Board of Directors authorized an increase to its existing share repurchase program pursuant to which CoreCivic may purchase up to an additional $200 million in

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease GlobeNewswire November 10, 2025 MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a futility determination based on medical monitoring data This outcome does

LifeMD to Participate in the BTIG Digital Health Forum

LifeMD to Participate in the BTIG Digital Health Forum GlobeNewswire November 10, 2025 NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on November 24, 2025. Management will participate in a

Scroll to Top